STOCK TITAN

[Form 4] Medifast, Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Director Andrea B Thomas of Medifast received 11,168 restricted stock units (RSUs) on June 25, 2025, as part of the Director's Deferred Compensation Plan. The RSUs were granted under the company's Amended and Restated 2012 Share Incentive Plan.

Key details of the transaction:

  • RSUs were granted at $0 cost to the director
  • Each unit represents one share of Medifast common stock
  • Full vesting scheduled for June 25, 2026
  • Following the transaction, Thomas owns 24,017.123 shares directly

This grant represents standard director compensation rather than an open market transaction. The filing was submitted by attorney-in-fact Jason L. Groves on June 26, 2025, within the required reporting timeframe.

Il direttore Andrea B Thomas di Medifast ha ricevuto 11.168 unità di azioni vincolate (RSU) il 25 giugno 2025, nell'ambito del Piano di Compensazione Differita per i Direttori. Le RSU sono state assegnate secondo il Piano Incentivi Azionari Modificato e Ristabilito del 2012 della società.

Dettagli principali della transazione:

  • Le RSU sono state concesse al direttore senza alcun costo
  • Ogni unità rappresenta una azione ordinaria di Medifast
  • La maturazione completa è prevista per il 25 giugno 2026
  • Dopo la transazione, Thomas detiene direttamente 24.017,123 azioni

Questa assegnazione rappresenta una compensazione standard per il direttore e non una transazione sul mercato aperto. La comunicazione è stata presentata dall’avvocato rappresentante Jason L. Groves il 26 giugno 2025, entro i tempi di segnalazione richiesti.

El director Andrea B Thomas de Medifast recibió 11,168 unidades restringidas de acciones (RSUs) el 25 de junio de 2025, como parte del Plan de Compensación Diferida para Directores. Las RSUs fueron otorgadas bajo el Plan de Incentivos de Acciones Modificado y Reestablecido de 2012 de la compañía.

Detalles clave de la transacción:

  • Las RSUs se concedieron al director sin costo alguno
  • Cada unidad representa una acción común de Medifast
  • La adquisición total está programada para el 25 de junio de 2026
  • Tras la transacción, Thomas posee directamente 24,017.123 acciones

Esta concesión representa una compensación estándar para directores y no una transacción en el mercado abierto. El reporte fue presentado por el apoderado Jason L. Groves el 26 de junio de 2025, dentro del plazo requerido para informes.

메디패스트의 이사 Andrea B Thomas는 2025년 6월 25일 이사 연기 보상 계획의 일환으로 11,168개의 제한 주식 단위(RSUs)를 받았습니다. 이 RSU는 회사의 2012년 개정 및 재확인 주식 인센티브 계획에 따라 부여되었습니다.

거래 주요 내용:

  • RSU는 이사에게 비용 없이 부여됨
  • 각 단위는 메디패스트 보통주 1주를 의미함
  • 완전 권리 획득 예정일은 2026년 6월 25일
  • 거래 후 Thomas는 직접 24,017.123주를 보유함

이번 부여는 공개 시장 거래가 아닌 표준 이사 보상에 해당합니다. 해당 보고는 법정 대리인 Jason L. Groves가 2025년 6월 26일 정해진 보고 기간 내에 제출하였습니다.

Le directeur Andrea B Thomas de Medifast a reçu 11 168 unités d’actions restreintes (RSU) le 25 juin 2025, dans le cadre du Plan de Rémunération Différée des Administrateurs. Les RSU ont été attribuées selon le Plan d’Incitation en Actions modifié et révisé de 2012 de la société.

Détails clés de la transaction :

  • Les RSU ont été attribuées au directeur sans coût
  • Chaque unité représente une action ordinaire de Medifast
  • L’acquisition complète est prévue pour le 25 juin 2026
  • Après la transaction, Thomas détient directement 24 017,123 actions

Cette attribution constitue une rémunération standard pour un administrateur et non une transaction sur le marché ouvert. Le dépôt a été effectué par le mandataire Jason L. Groves le 26 juin 2025, dans les délais requis.

Direktor Andrea B Thomas von Medifast erhielt am 25. Juni 2025 11.168 Restricted Stock Units (RSUs) im Rahmen des Directors Deferred Compensation Plan. Die RSUs wurden gemäß dem geänderten und neu gefassten Aktienanreizplan 2012 des Unternehmens gewährt.

Wesentliche Details der Transaktion:

  • Die RSUs wurden dem Direktor kostenfrei gewährt
  • Jede Einheit entspricht einer Medifast-Stammaktie
  • Vollständige Unbedingtheit ist für den 25. Juni 2026 geplant
  • Nach der Transaktion hält Thomas direkt 24.017,123 Aktien

Diese Zuteilung stellt eine standardmäßige Vergütung für Direktoren dar und keine Transaktion am offenen Markt. Die Meldung wurde vom Bevollmächtigten Jason L. Groves am 26. Juni 2025 fristgerecht eingereicht.

Positive
  • None.
Negative
  • None.

Il direttore Andrea B Thomas di Medifast ha ricevuto 11.168 unità di azioni vincolate (RSU) il 25 giugno 2025, nell'ambito del Piano di Compensazione Differita per i Direttori. Le RSU sono state assegnate secondo il Piano Incentivi Azionari Modificato e Ristabilito del 2012 della società.

Dettagli principali della transazione:

  • Le RSU sono state concesse al direttore senza alcun costo
  • Ogni unità rappresenta una azione ordinaria di Medifast
  • La maturazione completa è prevista per il 25 giugno 2026
  • Dopo la transazione, Thomas detiene direttamente 24.017,123 azioni

Questa assegnazione rappresenta una compensazione standard per il direttore e non una transazione sul mercato aperto. La comunicazione è stata presentata dall’avvocato rappresentante Jason L. Groves il 26 giugno 2025, entro i tempi di segnalazione richiesti.

El director Andrea B Thomas de Medifast recibió 11,168 unidades restringidas de acciones (RSUs) el 25 de junio de 2025, como parte del Plan de Compensación Diferida para Directores. Las RSUs fueron otorgadas bajo el Plan de Incentivos de Acciones Modificado y Reestablecido de 2012 de la compañía.

Detalles clave de la transacción:

  • Las RSUs se concedieron al director sin costo alguno
  • Cada unidad representa una acción común de Medifast
  • La adquisición total está programada para el 25 de junio de 2026
  • Tras la transacción, Thomas posee directamente 24,017.123 acciones

Esta concesión representa una compensación estándar para directores y no una transacción en el mercado abierto. El reporte fue presentado por el apoderado Jason L. Groves el 26 de junio de 2025, dentro del plazo requerido para informes.

메디패스트의 이사 Andrea B Thomas는 2025년 6월 25일 이사 연기 보상 계획의 일환으로 11,168개의 제한 주식 단위(RSUs)를 받았습니다. 이 RSU는 회사의 2012년 개정 및 재확인 주식 인센티브 계획에 따라 부여되었습니다.

거래 주요 내용:

  • RSU는 이사에게 비용 없이 부여됨
  • 각 단위는 메디패스트 보통주 1주를 의미함
  • 완전 권리 획득 예정일은 2026년 6월 25일
  • 거래 후 Thomas는 직접 24,017.123주를 보유함

이번 부여는 공개 시장 거래가 아닌 표준 이사 보상에 해당합니다. 해당 보고는 법정 대리인 Jason L. Groves가 2025년 6월 26일 정해진 보고 기간 내에 제출하였습니다.

Le directeur Andrea B Thomas de Medifast a reçu 11 168 unités d’actions restreintes (RSU) le 25 juin 2025, dans le cadre du Plan de Rémunération Différée des Administrateurs. Les RSU ont été attribuées selon le Plan d’Incitation en Actions modifié et révisé de 2012 de la société.

Détails clés de la transaction :

  • Les RSU ont été attribuées au directeur sans coût
  • Chaque unité représente une action ordinaire de Medifast
  • L’acquisition complète est prévue pour le 25 juin 2026
  • Après la transaction, Thomas détient directement 24 017,123 actions

Cette attribution constitue une rémunération standard pour un administrateur et non une transaction sur le marché ouvert. Le dépôt a été effectué par le mandataire Jason L. Groves le 26 juin 2025, dans les délais requis.

Direktor Andrea B Thomas von Medifast erhielt am 25. Juni 2025 11.168 Restricted Stock Units (RSUs) im Rahmen des Directors Deferred Compensation Plan. Die RSUs wurden gemäß dem geänderten und neu gefassten Aktienanreizplan 2012 des Unternehmens gewährt.

Wesentliche Details der Transaktion:

  • Die RSUs wurden dem Direktor kostenfrei gewährt
  • Jede Einheit entspricht einer Medifast-Stammaktie
  • Vollständige Unbedingtheit ist für den 25. Juni 2026 geplant
  • Nach der Transaktion hält Thomas direkt 24.017,123 Aktien

Diese Zuteilung stellt eine standardmäßige Vergütung für Direktoren dar und keine Transaktion am offenen Markt. Die Meldung wurde vom Bevollmächtigten Jason L. Groves am 26. Juni 2025 fristgerecht eingereicht.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Thomas Andrea B

(Last) (First) (Middle)
C/O MEDIFAST, INC.
100 INTERNATIONAL DRIVE

(Street)
BALTIMORE MD 21202

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
MEDIFAST INC [ MED ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
06/25/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 06/25/2025 A 11,168(1) A $0 24,017.123 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. These restricted stock units were granted under the Medifast, Inc. Director's Deferred Compensation Plan, as Amended and Restated (the "Plan"), in connection with the payment of the reporting person's annual director fees. Each unit represents the right to receive one share of the Issuer's common stock. These shares are granted from the Issuer's Amended and Restated 2012 Share Incentive Plan and will vest in full on June 25, 2026.
Remarks:
/s/ Jason L. Groves, attorney-in-fact 06/26/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many restricted stock units (RSUs) did MED director Andrea Thomas receive on June 25, 2025?

Andrea Thomas received 11,168 restricted stock units (RSUs) on June 25, 2025, as part of Medifast's Director's Deferred Compensation Plan. These units were granted at a price of $0.

When will Andrea Thomas's MED RSUs vest?

The restricted stock units granted to Andrea Thomas will vest in full on June 25, 2026, one year after the grant date. Each unit represents the right to receive one share of Medifast's common stock.

How many shares of MED stock does Andrea Thomas own after the June 2025 RSU grant?

Following the RSU grant transaction, Andrea Thomas beneficially owns 24,017.123 shares of Medifast (MED) stock directly. This includes the newly granted RSUs and previously held shares.

What is the source of MED's RSU grants to Andrea Thomas?

The RSUs were granted under Medifast's Director's Deferred Compensation Plan and sourced from the company's Amended and Restated 2012 Share Incentive Plan. The grant was made in connection with the payment of annual director fees.
Medifast

NYSE:MED

MED Rankings

MED Latest News

MED Latest SEC Filings

MED Stock Data

146.29M
10.69M
2.55%
83.35%
12.75%
Personal Services
Miscellaneous Food Preparations & Kindred Products
Link
United States
OWINGS MILLS